Form 4: Apellis Director Paul Fonteyne Receives Equity Grants

Apellis Pharmaceuticals Director Paul R. Fonteyne was granted 7,961 restricted stock units and 14,684 stock options on January 1, 2026.

Summary

• Paul R. Fonteyne, a Director of Apellis Pharmaceuticals, Inc. (APLS), acquired 7,961 shares of common stock through a restricted stock unit (RSU) grant on January 1, 2026.
• The RSUs were granted at a price of $0 and will fully vest on the first anniversary of the grant date, contingent on his continued service as a director.
• Fonteyne also acquired 14,684 stock options on January 1, 2026, with an exercise price of $25.12 per share.
• These stock options vest quarterly on the last day of each quarter from the grant date, subject to his continued service as a director, and expire on December 31, 2033.
• Following these transactions, Fonteyne beneficially owns 30,666 shares of common stock and 14,684 stock options.

Sentiment

Score: 7

Explanation: The filing reports standard equity compensation for a director, which is a positive sign of alignment between management and shareholder interests, without any negative implications.

Positives

• Director Paul R. Fonteyne received a grant of 7,961 restricted stock units, aligning his interests with long-term shareholder value.
• Fonteyne also received a grant of 14,684 stock options with an exercise price of $25.12, providing an incentive for future stock price appreciation.
• The equity grants demonstrate continued commitment from a key director to the company's future performance.

Future Outlook

The vesting schedules for both the restricted stock units (one year) and stock options (quarterly) indicate a long-term incentive structure tied to the director's continued service and the company's future performance.

Industry Context

Equity grants to directors are a common practice in the biotechnology and pharmaceutical industries, serving to align the interests of board members with those of shareholders and to incentivize long-term strategic oversight and value creation. The specific terms of these grants are consistent with typical compensation structures for non-employee directors in the sector.

Comparison to Industry Standards

• Equity compensation for non-employee directors, including restricted stock units and stock options, is a standard practice across the biotechnology and pharmaceutical industries.
• The vesting schedules (one-year for RSUs, quarterly for options) and option term (seven years) are generally within the typical range observed for director compensation packages in comparable companies.
• The size of the grant (7,961 RSUs and 14,684 options) would need to be benchmarked against peer companies of similar market capitalization and stage of development to assess its relative competitiveness and alignment with industry norms.

Corporate Governance

Related Party Transactions

• The equity grants to Director Paul R. Fonteyne represent a related party transaction, as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grants align the director's interests with shareholders by incentivizing long-term stock performance and continued strategic oversight.
• Employees: No direct impact on general employees is indicated by this specific filing.
• Management: Reinforces the compensation structure for non-executive directors, which is part of overall corporate governance.

Next Steps

• The 7,961 restricted stock units will fully vest on January 1, 2027, subject to continued service.
• The 14,684 stock options will vest quarterly from January 1, 2026, subject to continued service, and will expire on December 31, 2033.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director, which is a standard compensation practice and generally viewed as a neutral to slightly positive event as it aligns director incentives with shareholder interests. It does not provide new fundamental information that would warrant a change in investment recommendation, thus a 'hold' stance is maintained based solely on this filing.

Keywords

Apellis Pharmaceuticals, APLS, Paul R. Fonteyne, Director, SEC Form 4, Restricted Stock Units, RSU, Stock Options, Equity Grant, Insider Transaction, Beneficial Ownership